Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Sirolimus

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 80195 refers to a laboratory test specifically designed to measure the levels of sirolimus in the blood. Sirolimus, also known by its brand name Rapamune, is classified as an immunosuppressant medication. It plays a crucial role in preventing the body’s immune system from rejecting transplanted organs, such as kidneys, livers, and hearts. The administration of sirolimus can occur either as a standalone treatment or in conjunction with other immunosuppressive agents to enhance its effectiveness. Due to its narrow therapeutic range, careful monitoring of sirolimus levels is essential to ensure that the drug remains within a safe and effective concentration in the bloodstream. Initially, blood levels may be assessed daily when starting therapy, then tapering to 1-2 times per week, and eventually to once every 1-2 months for ongoing management. For routine monitoring, blood specimens are collected as trough levels, which means the sample is taken immediately before the next scheduled dose and at least 12 hours after the previous dose. The blood sample is obtained through a venipuncture, which is a separately reportable procedure. The testing of sirolimus levels is performed using advanced techniques such as liquid chromatography-tandem mass spectrometry, although it may also be analyzed using chromatographic or immunoassay methods, which can yield slightly different results.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The sirolimus blood test (CPT® Code 80195) is indicated for the following conditions:

  • Organ Transplantation This test is primarily performed for patients who have undergone organ transplantation, such as kidney, liver, or heart transplants, to monitor the effectiveness of sirolimus in preventing organ rejection.
  • Therapeutic Drug Monitoring It is used to ensure that sirolimus levels remain within the therapeutic range, which is critical for maximizing efficacy while minimizing toxicity.
  • Adjustment of Dosage The test helps in adjusting the dosage of sirolimus based on the measured blood levels, particularly during the initiation of therapy or when there are changes in the patient's condition.

2. Procedure

The procedure for measuring sirolimus levels involves several key steps:

  • Step 1: Patient Preparation Prior to the blood draw, the patient should be informed about the test and the importance of timing the sample collection. The blood sample should be collected as a trough level, meaning it should be taken immediately before the next scheduled dose of sirolimus and at least 12 hours after the last dose.
  • Step 2: Venipuncture A qualified healthcare professional will perform a venipuncture to obtain a blood sample. This procedure involves inserting a needle into a vein, typically in the arm, to draw the necessary volume of blood for testing. The venipuncture is a separately reportable procedure and must be documented accordingly.
  • Step 3: Sample Handling Once the blood sample is collected, it must be properly labeled and handled to ensure accurate testing. The sample is then sent to the laboratory for analysis.
  • Step 4: Laboratory Testing In the laboratory, the whole blood sample is analyzed using liquid chromatography-tandem mass spectrometry, which is a highly sensitive and specific method for measuring sirolimus levels. Alternatively, chromatographic or immunoassay techniques may be employed, depending on the laboratory's capabilities.

3. Post-Procedure

After the blood sample has been collected, there are no specific post-procedure care requirements for the patient. However, it is important for the healthcare provider to communicate the results of the sirolimus level test to the patient and adjust the medication dosage as necessary based on the findings. Regular monitoring may be required, especially during the initial phases of therapy or when there are changes in the patient's health status. Patients should be advised to report any side effects or concerns related to their sirolimus therapy to their healthcare provider promptly.

Short Descr ASSAY OF SIROLIMUS
Medium Descr DRUG SCREEN QUANTITATIVE SIROLIMUS
Long Descr Sirolimus
Status Code Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
CLIA Waived (QW) No
APC Status Indicator Conditionally packaged laboratory tests
Type of Service (TOS) 5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS) T1H - Lab tests - other (non-Medicare fee schedule)
MUE 2
CCS Clinical Classification 235 - Other Laboratory
90 Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.
Q1 Routine clinical service provided in a clinical research study that is in an approved clinical research study
26 Professional component: certain procedures are a combination of a physician or other qualified health care professional component and a technical component. when the physician or other qualified health care professional component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.
77 Repeat procedure by another physician or other qualified health care professional: it may be necessary to indicate that a basic procedure or service was repeated by another physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 77 to the repeated procedure or service. note: this modifier should not be appended to an e/m service.
Q4 Service for ordering/referring physician qualifies as a service exemption
59 Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
76 Repeat procedure or service by same physician or other qualified health care professional: it may be necessary to indicate that a procedure or service was repeated by the same physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 76 to the repeated procedure or service. note: this modifier should not be appended to an e/m service.
91 Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.
GA Waiver of liability statement issued as required by payer policy, individual case
GW Service not related to the hospice patient's terminal condition
Date
Action
Notes
2013-01-01 Changed Medium description changed per AMA 2013 corrections document dated January 25, 2013.
2006-01-01 Added First appearance in code book in 2006.
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"